News headlines about Eyenovia (NASDAQ:EYEN) have trended somewhat positive on Thursday, Accern Sentiment reports. The research group rates the sentiment of media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Eyenovia earned a media sentiment score of 0.06 on Accern’s scale. Accern also gave news stories about the company an impact score of 45.3081709900997 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Shares of EYEN stock traded up $0.20 during trading on Thursday, hitting $5.39. 15,300 shares of the company were exchanged, compared to its average volume of 16,245. The stock has a market cap of $50.99 million and a P/E ratio of -2.46. Eyenovia has a twelve month low of $4.70 and a twelve month high of $10.74.
Eyenovia (NASDAQ:EYEN) last posted its quarterly earnings results on Tuesday, August 14th. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.09. analysts predict that Eyenovia will post -1.73 EPS for the current fiscal year.
Separately, Zacks Investment Research upgraded shares of Eyenovia from a “hold” rating to a “buy” rating and set a $6.25 price target for the company in a report on Friday, August 17th.
In related news, CEO Tsontcho Ianchulev purchased 6,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 28th. The stock was acquired at an average cost of $6.63 per share, for a total transaction of $39,780.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 48.20% of the company’s stock.
Eyenovia, Inc, a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States. It is developing MicroProst, which is in Phase III clinical trials for the treatment of chronic angle closure glaucoma; MicroStat, which is in Phase III clinical trials for the treatment of mydriasis; MicroTears for the treatment of dry eye; and MicroPine for the treatment of myopia.
Featured Article: Dividend
Receive News & Ratings for Eyenovia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyenovia and related companies with MarketBeat.com's FREE daily email newsletter.